Bristol Myers (BMY) Stock: Here’s What You Need To Know

Bristol Myers (NYSE:BMY) On August 5, 2016 Bristol Myers had a very rough day with respect to one of its targets in the pipeline. ┬áThe company’s PD-1 immune checkpoint inhibitor, known as Opdivo, failed to meet the primary endpoint of a phase 3 clinical trial. Bristol Myer’s stock did not have a good day after … Read more